LymphoVi: Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region

• Sponsor: Centre Hospitalier Universitaire Dijon (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT04859920
• Collaborator: (none)
• Enrollment: 159
• Location: 1
• Anticipated Duration (Months): 12
• Patients Per Site Per Month: 13.3

Study Details

Study Description

Brief Summary

The development of new diagnostic tools and targeted therapy have significantly improved the management of non-Hodgkin's malignant lymphomas and thus their long-term prognosis. However, in the study of improved patient management, survival is not the only measurable indicator and preservation of quality of life is an essential component. In addition, there is little existing data regarding the determinants of quality of life in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) in the general population in France.

Condition or Disease	Intervention/Treatment	Phase
Diffuse Large Cell Diffuse Lymphoma; Follicular Lymphoma	Other: Questionnaires; Other: Collection of clinical data and treatments

Study Design

• Study Type: Observational
• Anticipated Enrollment: 159 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region
• Anticipated Study Start Date: May 1, 2021
• Anticipated Primary Completion Date: May 1, 2022
• Anticipated Study Completion Date: May 1, 2022

Outcome Measures

Primary Outcome Measures

1. Generic Questionnaire SF-12 [At inclusion]

2. Specific questionnaire QLQ-C30 [At inclusion]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• Patients diagnosed with DLBCL or FL between January 1, 2010 and December 31, 2017,

• Alive as of January 1, 2021,

• Updated patient address.

Exclusion Criteria:

• Other forms of Hematologic Malignancies at diagnosis,

• Minors.

• Person subject to legal protection (curatorship, guardianship)

• Person subject to a judicial safeguard measure

• Pregnant, parturient or breastfeeding woman

• Adults incapable of giving consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Chu Dijon Bourogne	Dijon		France	21000

Sponsors and Collaborators

• Centre Hospitalier Universitaire Dijon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Centre Hospitalier Universitaire Dijon
• ClinicalTrials.gov Identifier: NCT04859920
• Other Study ID Numbers: MAYNADIE 2020
• First Posted: Apr 26, 2021
• Last Update Posted: Apr 26, 2021
• Last Verified: Apr 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin

Study Results

No Results Posted as of Apr 26, 2021